Enlivex Therapeutics’ (ENLV) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a research note published on Friday,Benzinga reports. The firm currently has a $13.00 target price on the stock.

Enlivex Therapeutics Trading Up 6.8 %

Shares of ENLV opened at $1.10 on Friday. Enlivex Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.59. The stock has a 50 day moving average of $1.18 and a 200-day moving average of $1.29.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings data on Friday, November 29th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.04. Analysts expect that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

Institutional Trading of Enlivex Therapeutics

A hedge fund recently bought a new stake in Enlivex Therapeutics stock. Sigma Investment Counselors Inc. bought a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 30,000 shares of the company’s stock, valued at approximately $50,000. Sigma Investment Counselors Inc. owned about 0.14% of Enlivex Therapeutics at the end of the most recent quarter. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.